Cargando…
Reply to: RAAS inhibitors in COVID-19: not all are created equal!
Autores principales: | Gonçalves, Jorge, Santos, Catarina D., Fresco, Paula, Fernandez-Llimos, Fernando |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier España, S.L.U. on behalf of Sociedade Portuguesa de Cardiologia.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288312/ https://www.ncbi.nlm.nih.gov/pubmed/37356667 http://dx.doi.org/10.1016/j.repc.2023.06.003 |
Ejemplares similares
-
RAAS inhibitors in COVID-19: not all are created equal!
por: Kow, Chia Siang, et al.
Publicado: (2023) -
Potential use of renin-angiotensin-aldosterone system inhibitors to reduce COVID-19 severity
por: Gonçalves, Jorge, et al.
Publicado: (2023) -
Reply: Not all incomplete revascularizations are created equal
por: Weiss, Aaron J., et al.
Publicado: (2021) -
All Purkinje cells are not created equal
por: Albergaria, Catarina, et al.
Publicado: (2014) -
Reply to: ‘Interaction between RAAS inhibitors and ACE2 in the context of COVID-19’
por: Zheng, Ying-Ying, et al.
Publicado: (2020)